Press Releases

Filters (1)
March 1, 2021

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant

Read more
October 1, 2020

Debiopharm Launches Trilynx – A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head &…

Read more
September 17, 2020

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

Read more
August 13, 2020

Debiopharm’s IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients

Read more
February 27, 2020

FDA grants Breakthrough Therapy Designation for Debiopharm’s novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer

Read more
September 30, 2019

Debiopharm’s novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

Read more
September 3, 2019

Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients

Read more
April 1, 2019

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

Read more
June 15, 2017

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Read more